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Abstract: Objective: The current pilot study investigated whether patients with concurrent 
substance use disorders and eating disorders (SUD and ED) who experienced a reduction in 
SUD and ED symptoms following treatment for SUD and ED also experienced a reduction 
in personality disorder (PD) symptoms. Method: Twenty patients with SUD and ED and PD 
were assessed pre and post treatment using clinical interviews, self-report questionnaires, 
and a therapist questionnaire on DSM-IV-TR symptoms for PD. Results: Symptoms for the 
personality disorders were reduced following treatment. This reduction was correlated with 
a decrease in the number of symptoms of ED at post treatment. Discussion:  Chronic 
concurrent SUD and ED may make it difficult to separate PD symptoms from co-occurring 
disorders. Many features attributed to PDs may be reduced when problematic substance use 
and disordered eating are addressed, a fact that may increase clinician and patients’optimism 
about therapeutic change.  
Keywords:  substance use disorders; eating disorders; personality disorders; avoidant 
personality disorder; borderline personality disorder; obsessive compulsive personality 
disorder 
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1. Introduction 
 
A growing body of literature suggests that there is substantial comorbidity between substance use 
disorders (SUD) and eating disorders (ED). Depending on the criteria used to make the diagnoses, ED 
can occur in up to 32% of substance use cases [1-9]. In turn, substance use has been found to occur in 
up to 49% of people with ED [10-19]. 
Individuals with concurrent SUD and ED are frequently diagnosed with multiple comorbid clinical 
disorders, including personality disorders (PDs) (between 11.7–26%) [20-22]. Personality disorders 
are characterized by “an enduring pattern of inner experience and behavior that deviates markedly 
from the expectations of the individual’s culture, is pervasive and inflexible, has an onset in 
adolescence or early adulthood, is stable over time, and leads to distress or impairment” [23]. In the 
general community, the most prevalent PDs are Borderline Personality Disorder (BPD), affecting 2% 
of adults, mostly young women [24], Avoidant Personality Disorder (Avoidant), affecting 2.4% of 
adults, and Obsessive-Compulsive Personality Disorder (OCPD) affecting 7.9% of adults [25]. BPD is 
defined as “a pervasive pattern of instability of interpersonal relationships, self-image, and affects, and 
marked impulsivity” [26]. Avoidant PD is defined as “a pervasive pattern of social inhibition, feelings 
of inadequacy, and hypersensitivity to negative evaluation” [27].  OCPD is defined as “a   
pre-occupation with orderliness, perfectionism, and mental and interpersonal control” [28]. 
Comorbidity of the Cluster B PD has been found to be more common for patients with concurrent 
SUD and ED, than for those with ED only [29]. In patients diagnosed with anorexia nervosa (AN) and 
bulimia nervosa (BN), 56% have also been diagnosed with comorbid PDs [30]. In patients diagnosed 
with binge-eating disorder (BED), 20% have been found to meet criteria for concurrent PDs [31]. 
Additionally, up to 65% of individuals seeking treatment for SUD have been diagnosed with active 
BPD [32]. In a sample of treatment-seeking patients diagnosed with concurrent SUD ED, 26% were 
diagnosed with comorbid BPD, 18.2% with OCPD, and 11.7% with Avoidant PD [33]. This 
comorbidity carries a high individual and societal cost. These individuals have difficulty maintaining 
employment, financial stability, and meaningful interpersonal relationships [30,31].  
Clinicians involved in the treatment of concurrent SUD and ED at an Eating Disorders and 
Addiction Clinic (EDAC) at a large mental health and research facility have reported for several years 
that most individuals who meet criteria for PDs at the start of treatment no longer meet the criteria 
after treatment for concurrent SUD and ED. A few published studies provide support for these clinical 
observations. In a sample of patients with long standing eating disorders, Oyvind and colleagues [34] 
reported a high commorbidity of personality disorders and a reduction in PDs from 77% at admission 
to an eating disorder treatment to 57% at 2-year follow-up. In a 5 year follow-up study, Vrabel, 
Martinsen, Hoffart and Rosenvinge [35] found that patients who recovered from ED had a lower 
frequency of PDs. Oyvind and colleagues [36] observed that in general, ED symptomatic changes 
occurred prior to changes in PD, thus suggesting that PD could be a consequence of ED 
symptomatology. While a reduction of PD has been observed following treatment for ED, it is not 
known if similar findings can occur in a sample of clients with concurrent ED and SUD as SUD is 
associated with poor treatment outcome [37]. 
The objective of this pilot study was to assess whether patients with concurrent SUD, ED, and PDs 
experienced a reduction in the number of PD symptoms after receiving treatment for their concurrent Int. J. Environ. Res. Public Health 2009, 6          
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SUD and ED. A decrease in the number of symptoms and diagnoses was explored specifically for the 
three most frequently occurring PDs in the concurrent SUD and ED population presenting for 
concurrent treatment, and reported in the literature [38,39]. These three PDs are Borderline, Avoidant, 
and Obsessive-Compulsive. 
It was hypothesized that patients who participated in a concurrent treatment program for SUD and 
ED and who experienced a significant reduction of SUD and ED symptoms would be more likely to 
significantly reduce their BPD, Avoidant PD, and OCPD symptoms following treatment compared to 
those patients who were less successfully treated for their concurrent SUD and ED.  
 
2. Method 
 
2.1. Participants and Procedure 
 
The sample consisted of 20 outpatients who completed a concurrent treatment program for SUD 
and ED within a large metropolitan mental health centre. Exclusion criteria for the study included 
patients demonstrating evidence of mental retardation, active psychosis, or chronic self-harm and/or 
suicidal attempts/gestures. The sample was comprised of 17 (85%) females and three (15%) males 
diagnosed at pre-treatment with active SUD, ED and PDs (BPD, Avoidant PD, and OCPD). 
Patients were administered the Structured Clinical Interview for DSM (SCID) Axis I   
diagnoses [37], for Axis II diagnoses [38], and other SUD, ED, and mental health assessment measures 
(see Section 2.2.1.) to determine eligibility in the treatment and severity of symptoms. Subsequently, 
they were asked to volunteer for a study on concurrent SUD and ED. All patients who were informed 
about the study agreed to participate, 
Patients eligible for enrollment in a concurrent treatment program for SUD and ED were free to 
accept, reject, and withdraw from the treatment and study at any time. All patients provided informed 
signed consent for their data to be used for research purposes, and ethical guidelines were strictly 
followed. Patients received an outpatient psychobehavioural specialized treatment for concurrent SUD 
and ED that included weekly individual and group treatment, as well as meetings with dieticians and 
psychiatrists as needed. The individual and group psychotherapy treatment included psychoeducation 
about SUD, ED, coping and nutrition. Motivational interviewing, mindfulness training, and 
BT/CBT/DBT were interventions employed. The focus of the treatment was to eliminate or reduce 
substance use and eating disordered behaviours. It was not to target PD. Patients monitored their 
substance use and ED behaviours and urges in daily logs and discussed these in groups as well as 
problems they may have had implementing adaptive coping strategies. Patients learned adaptive 
techniques to reduce their urges to use substances or engage in problematic eating and restricting. They 
were taught to identify personal triggers and reduce the vulnerability to those triggers. They learned to 
adopt healthier eating and sleeping habits and ways to monitor their emotions and respond adaptively 
(as opposed to react negatively) to them. Patients were guided on living in the moment as opposed to 
dwelling on the past and/or worrying about the future. They were also trained to develop and practice 
assertiveness skills, create a balanced lifestyle, identify and challenge dysfunctional cognitions, 
explore new activities and interests, eliminate toxic relationships and develop new healthier ones.  Int. J. Environ. Res. Public Health 2009, 6          
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There was variability in the amount of treatment received, but on average patients attended 67.8 
(SD = 46) individual sessions, 49.1 (SD = 29.7) 2 hour group sessions, 2.5 (SD = 4.7) appointments 
with a dietician, and 11.4 (SD = 9.2) phone coaching sessions. In addition, six patients also attended an 
average of 7.7 (SD = 5.5) appointments with a psychiatrist within the program (to prescribe and 
monitor the use of psychotropic medication). Six of the patients were prescribed psychotropic 
medication for at least a portion of their treatment. These medications included Serzone, Effexor, 
Celexa, Fluoxetine, Prozac, Diazepam, and Surmontil. Two patients attended appointments with a 
counselor (four and 28 sessions) to deal with addiction medicine issues (one case involving methadone 
treatment), and one patient received 15 vocational counseling sessions. Patients remained in the 
program from 12 to 45 months, with an average of 21.4 months (SD = 10.2).  
Assessments of patients were completed at pre-treatment and post-treatment. Clinicians involved in 
the assessments and treatments were blind to the study hypotheses. A doctoral-level research associate 
who was not involved in the assessment or treatment of these patients conducted the review of data for 
all patients who had completed the treatment program. To explore whether a reduction in the number 
of symptoms of SUD, ED, and the three PDs of interest (BPD, Avoidant PD, and OCPD) occurred at 
post-treatment, data was collected for both the pre- and post-treatment assessment phases.  
 
2.2. Sources of Data 
 
The following measures have been chosen for their excellent psychometric properties and ease of 
administration. 
Structured Clinical Interview for DSM diagnoses (SCID) [40,41].  The SCID is a structured 
interview administered by trained clinicians to determine presence or absence of DSM Axis I clinical 
diagnoses and Axis II personality disorders.  It is one of the most frequently used instruments to 
identify clinical and personality disorders in clinical research. In this study, the SCID was used to 
determine treatment eligibility and confirm presence of active SUD, ED, and the three PDs of interest. 
Presence of other concurrent Axis I and II disorders were also identified. In addition to the SCID, 
symptoms of SUD, PD and ED were assessed with the following respective instruments. 
Beck Depression Inventory (BDI) [42].  The BDI is a 21-item self-report questionnaire which 
measures symptoms of depressed mood, including suicidal ideation, irritability, and anhedonia. 
Current severity of symptoms over the past week is assessed. Higher scores reflect greater severity of 
depression.  
Beck Anxiety Inventory (BAI) [43]. The BAI is a 21-item self-report questionnaire which measures 
general symptoms of anxiety, including physiological responses. Current severity of anxiety over the 
past week is assessed, and higher scores reflect a greater level of anxiety.  
Symptom Checklist-90-Revised (SCL-90-R) [44]. The SCL-90-R is a 90-item self-report symptom 
inventory that assesses psychopathology and measures current level of distress (over the past two 
weeks) on nine primary symptom dimensions and three global indices of distress. The dimensions 
include: Depression, Anxiety, Paranoid Ideation, Psychoticism, Interpersonal Sensitivity, and 
Obsessive-Compulsive. Higher scores reflect greater level of distress and psychological disorder. 
Reflective Activity Scale (RAS) [45]. The RAS is a 39-statement inventory that assesses individual 
differences along a continuum ranging from being excessively preoccupied and inactive, to reflectively Int. J. Environ. Res. Public Health 2009, 6          
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active, to thoughtlessly reactive or impulsive.  The RA scale assesses the four dimensions of: (1) 
reflection, (2) action, (3) information gathering, and (4) over-absorption, with regards to facing 
problematic situations. Higher scores reflect higher tendency to reflect, take action, gather information, 
and be overly absorbed in the face of stressful situations.  
Toronto Alexithymia Scale-20 (TAS-20) [46]. The TAS is a 20-item scale that assesses alexithymia 
or affective deficits on three factors: Difficulty in Identifying Feelings, Difficulty in Describing 
Feelings, and Externally-Oriented Thinking.  A total score is also calculated.  Scores range from   
20–100. Scores of 61 or higher indicate alexithymia. 
The Eating Disorder Inventory (EDI) [47]. The EDI is a 64-item self-report questionnaire which 
measures attitudes, feelings, and behaviours related to eight dimensions of eating disturbance: Bulimia, 
Perfectionism, Drive for Thinness, Interoceptive Awareness, Interpersonal Distrust, Ineffectiveness, 
Body Dissatisfaction, and Maturity Fears.  Higher scores reflect greater disturbance on the eating 
dimensions. 
Eating Disorders Examination (EDE) [48]. The EDE is a semi-structured interview which assesses 
rigidity and severity of symptoms on four attitudinal disturbances related to eating disorders: Restraint, 
Eating Concern, Weight Concern, and Shape Concern. A Global Index of Severity of symptoms is also 
determined. Higher scores reflect greater severity in eating disturbance. 
Addiction Severity Index (ASI) [49]. The ASI is a structured interview which evaluates addiction 
severity and psychosocial impairment in six areas: 1) alcohol and drug abuse (e.g., number of 
overdoses, money spent on substances); 2) medical (e.g., hospitalizations); 3) employment (e.g., net 
income); 4) legal (e.g., number of convictions); 5) family/social (e.g., relationship discord); and 6) 
psychiatric problems (e.g., suicidality).  Questions include the number, duration, and extent of 
problems in the patient’s lifetime and in the past 30 days. Higher scores reflect greater severity in 
addiction.  
Drug-Taking Confidence Questionnaire for Alcohol (DTCQ-A) and for Drugs (DTCQ-D) [50]. 
The DTCQ-A and DTCQ-D are the 8-item brief versions of the original 50-item self-report 
questionnaires. These questionnaires measure impulsivity, coping self-efficacy, and level of 
confidence in being able to resist using a substance across different categories of high-risk-for-relapse 
crisis situations.  Lower scores reflect lower confidence, lower coping self-efficacy, and   
greater impulsivity. 
Therapist Questionnaire (TQ) [51].  The TQ designed for the study was used to identify PD 
psychopathology relating to BPD, Avoidant PD, and OCPD. The TQ contains 63 questions relating to 
all of the clinical features corresponding to BPD, Avoidant PD, and OCPD listed in the DSM-IV [52]. 
Therapists were asked to indicate presence of each symptom at pre-therapy and the presence, absence, 
or improvement of each symptom at post-therapy. Ratings were made at both pre-and post-treatment.  
 
2.3. Statistical Analysis 
 
Information from the standardized measures and therapist questionnaire were included in the data 
analysis to provide an indication of convergent validity to the responses by patients on their self-report 
measures. Change in symptoms of SUD, ED, and PD was computed by subtracting pre-treatment 
scores on the measures from post-treatment scores. Paired t-tests and chi-squared tests (as appropriate) Int. J. Environ. Res. Public Health 2009, 6          
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were conducted to assess change from pre- to post-treatment. Pearson correlations were conducted to 
identify association amongst relevant variables. Significance levels were corrected using Bonferroni 
adjustment for multiple comparisons.  
 
3. Results and Discussion  
 
The age of the patients in the study ranged from 21 to 59 years (mean = 36.6, SD = 2.04). Over a 
third of patients (35%) were single/never married. Twenty-five percent of patients had completed 
university, and 20% had completed some university. Most patients (60%) were either unemployed or 
on disability at the start of treatment and 5% were employed part-time. Most patients (60%) reported 
alcohol as their primary substance of concern. Half (50%) of the patients were diagnosed with BN at 
pre-treatment, and 30% with AN (Binge-Purge sub-type). As well, 40% of patients were diagnosed 
with BPD, 35% with Avoidant PD, and 30% with OCPD (these PD diagnoses were not mutually 
exclusive). One-quarter (25%) of patients had had previous therapy for an ED, and most patients 
(65%) were taking prescribed anti-depressants at pre-treatment.  
 
Table 1.  Change in pre- to post-treatment mean scores on measures for Borderline, 
Avoidant, and Obsessive-Compulsive personality disorder symptoms. 
 Pre-treatment  Post-treatment 
Variable  n  Mean  S.D. Mean    S.D. t  df  p 
SCL-90-R:  
Global Symptom Index 
High: >70 
Moderate: 60 – 69 
Average: 40 – 59 
Below average: <40 
20  69.78 7.53  58.78 11.10 4.59 19  0.000 
Depression  20  70.10 4.19  60.75 10.12 4.06 19  0.001 
Anxiety  18  65.61 10.58 59.89 9.18  2.58 17  0.010 
Interpersonal Sensitivity  20  69.10  8.14 59.25  9.59 5.32  19  0.000 
Psychoticism  20  68.20 8.17  59.40 8.33  4.36 19  0.000 
Paranoid  Ideation  20  62.05 10.80 52.10 9.11  5.67 19  0.000 
Obsessive  Compulsive  20  67.55 8.84  60.05 9.56  3.21 19  0.003 
BDI-Total Score 
Minimal: <14 
Mild: 14–19  
Moderate: 20–28 
Severe: >28  
20  21.75 7.46  12.80 9.94  3.40 19  0.002 
BAI-Total Score 
Minimal: <8 
Mild: 8 – 15 
Moderate: 16 – 25 
Severe: >25 
18 16.56  10.76  12.06  10.61  1.67  17  0.056 
RAS:              
Over-Absorption 
Minimal: <17  
Mild: 17–24 
Moderate: 25–32 
Severe: >32 
20  24.00 7.98  19.35  7.60  2.99  19  0.004 Int. J. Environ. Res. Public Health 2009, 6          
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Table 1. Cont. 
EDI:              
Interpersonal Distrust 
Low: <2.3 
Average: 2.3–5.1 
Elevated: 5.2–8 
Severe: >8.1  
18 6.94  5.06  3.56  3.42  3.94  17  0.000 
Perfectionism 
Low: <5.6 
Average: 5.6–9.5 
Elevated: 9.6–13.6 
Severe: >13.7 
18 9.33  5.42  7.44  4.68  2.34  17  0.016 
Ineffectiveness 
Low: <2.1 
Average: 2.1 
Elevated: 5.7 
Severe: >5.8 
18 15.21  7.36  7.21  4.99  4.17  17  0.000 
TAS:              
Total Score 
non-alexithymia: <52 
possible alexithymia: 52–60 
alexithymia: 61 
13 57.15  12.72  48.23  9.26  2.53  12  0.026 
Difficulty Identifying 
Feelings 
13  21.54 6.58  17.23  5.99  1.86  12 0.088 
Difficulty Describing 
Feelings 
13 16.08  5.52  13.38  5.28  2.23  12  0.04 
 
Note: SCL-90: Symptom Checklist-90-Revised; BDI: Beck Depression Inventory; BAI: Beck Anxiety 
Inventory; RAS: Reflective Activity Scale; TAS: Toronto Alexithymia Scale; EDI: Eating Disorder 
Inventory. 
 
Table 2.  Other symptom changes in pre- to post-treatment mean scores on treatment 
effectiveness measures for eating and substance use disorders. 
 Pre-treatment  Post-treatment 
Variable N  Mean  S.D.  Mean    S.D.  t  df  p 
Eating Disorder Examination 
Global Score 
Low: 0.127 
Average: 0.932 
Elevated:1.737 
Severe: 2.452 
16 3.74  0.98  1.52  1.04  5.96  15  0.000 
Eating Disorder Inventory 
Bulimia 
Low: <1.8 
Average: 1.8–4.8 
Elevated: 4.9–7.9 
Severe: >8.0 
18 9.11  5.12  2.89  4.70  4.33  17  0.000 Int. J. Environ. Res. Public Health 2009, 6          
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Table 2. Cont. 
Drive for Thinness 
Low: <5.0 
Average: 5.0–10.2 
Elevated: 10.3–15.5 
Severe: >15.6 
18 12.11  5.75  6.50  5.24  3.40  17  0.002 
Interceptive Awareness 
Low: <2.3 
Average: 2.3–5.7 
Elevated: 5.8–9.2 
Severe: 9.3 
18 11.56  5.85  4.72  6.94  3.19  17  0.003 
Alcohol Severity Index Composite Score: 
Alcohol 15  0.36  0.32  0.20  0.26  2.67  14  0.009 
Drug 14  0.15  0.16  0.08  0.08  1.42  13  0.002 
Drug-Taking Confidence Questionnaire: 
Alcohol 11  56.59  29.10  72.95  27.29  -1.59  10  0.072 
Drug 20  12.50  21.74  42.34  48.35  -3.43  19  0.001 
 
The number of personality symptoms present at pre-treatment for each of the three PDs (as 
indicated on the TQ) were statistically significantly reduced at post-treatment for BPD (χ² = 39.744,  
df = 24, t = 2.216, p = 0.040); for Avoidant (χ² = 43.214, df = 18, t = 2.717, p = 0.014); and for OCPD 
(χ² = 22.361, df = 24, t = 2.396, p = 0.028). Such statistically significant reductions in personality 
disorder symptoms are clinically significant as well given that in most cases patients’ diagnoses 
remitted during treatment. All nine patients who initially met criteria for OCPD, all but one of twelve 
patients with BPD, and all but one of twelve patients with APD, no longer met the diagnoses following 
treatment. The number of PD symptoms as measured by the TQ also decreased substantially from a 
mean of 4.6 (SD = 2.67) BPD symptoms to 1 (SD = 2.2.), from a mean of 2.7 OCPD symptoms  
(SD = 2.25) to 0.4 (SD = 0.821), and from a mean of 3.95 (SD = 2.7) to 0.4 (SD = 0.35)   
post treatment.  
As seen in Table 1, the results of paired t-test calculations showed significant decreases in the 
number of symptoms from pre- to post-treatment on various indices that measured relevant PD 
symptoms (see Table 1), and on the various indices of SUD and ED (see Table 2). For many of these 
scales and variables, mean scores changed from a greater category of severity to a lower category of 
severity. For example, the Global Symptom Index of the SCL-90 changed from a mean T score of 
69.78 (almost the 98th percentile), to 58.78, which is within the normal range (below one SD above the 
mean). This is the case for five out of the six subscales (the exception being Obsessive Compulsive) on this 
measure as well. For the BDI, patients’ mean score changed from being in the moderate severe range to the 
minimal range, and for the BAI, patients’ mean score changed from the moderate severe range to mild 
range. Patients’ mean scores were in the average range post- treatment for the following various scales that 
were elevated prior to treatment: Alexithymia, Interpersonal Distrust, Bulimia, Global Index of the Eating 
Disorder Examination, Drive for thinness, and Interceptive awareness. 
The PD symptom reductions were statistically significantly correlated with a decrease in number of 
symptoms of ED symptoms (on the EDE) at post-treatment for Avoidant PD (r = 0.686, p = 0.010), but 
not for OCDP (r = 0.311, p = 0.300) and BPD (r = 0.446, p = 0.146).  Although there were no Int. J. Environ. Res. Public Health 2009, 6          
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statistically significant correlations between PD symptom reductions and post-treatment decrease in 
SUD symptoms, a trend towards a decrease was apparent for BPD. The non-significance may be more 
the result of lack of power than lack of effect (r = 0.409, p = 0.211 for BPD, r = -0.118, p = 0.731 for 
Avoidant PD, r = 0.146, p = 0.668 for OCPD).  
 
4. Conclusions 
 
This pilot study explored whether patients with concurrent SUD, ED, and PDs experienced a 
reduction in the number of PD symptoms after receiving treatment for their concurrent SUD and ED. 
The PDs of interest were BPD, Avoidant PD, and OCPD. Half of the patients were diagnosed with BN 
and a third with AN (Binge-Purge sub-type). Almost half were diagnosed with BPD, over a third with 
Avoidant PD, and almost a third with OCPD. Their primary substance use of concern was alcohol. 
After undergoing concurrent SUD and ED treatment for an average length of almost 2 years, patients 
showed a reduction of SUD, ED, and PD symptoms that were both statistically and clinically 
significant.  These results are consistent with research on patients with ED who have similarly 
experienced a decrease in their ED and PD symptoms over the course of treatment for their ED [34].  
In our study, the PD symptom reductions were associated with a decrease in number of ED 
symptoms at post-treatment particularly evident for Avoidant PD. There was a trend for ED and SUD 
symptom reduction to be associated with a reduction in BPD symptoms. A larger sample size may 
clarify these findings. Although this is a pilot study and the number of patients is too low to draw firm 
definite conclusions about the relationship between concurrent SUD/ED and PD, the results raise 
several hypotheses to consider. First, the treatment may have affected the SUD, ED, and PD symptoms 
simultaneously. Treatment designed to decrease problematic substance use and eating often involves 
changing how a person manages emotions, copes with stress, resolves problems, relates to others, and 
thinks about him/herself and the world, all of which can be challenges for people with BPD, APD or 
OCPD. Working on such goals may inadvertently decrease PD symptomatology.  
Second, the reduction in ED and SUD symptoms may have resulted in a reduction of PD symptoms. 
Efforts to maintain an ED and SUD may require significant behavioural and personality changes, such 
as avoidance of people (a symptom of Avoidant PD) due to shame about disordered behaviour, disgust 
about appearance, or to prevent interruption during problematic eating and substance use. Similarly, 
patients with eating disorders may develop rigidity and compulsivity in adhering to strict routines to 
ensure that they do not gain weight, symptoms associated with OCPD. Additionally, patients with ED 
and SUD symptoms may develop PD like symptoms because of the physiological effects of their ED 
and SUD behaviours, such as difficulties in concentration and thinking, paranoid thinking, affective 
instability, all of which are common in BPD. When the ED and SUDs are in remission, these 
developed behaviours and personality changes may no longer be necessary and will begin to subside. 
Structural equation modeling used by Oyvind and colleagues [34] supports this hypothesis. In their 
hospital sample, patients exhibited changes in their eating disorder symptoms prior to changes in their 
personality disorder symptoms.  
Third, the reduction in PD symptoms might actually precede the reduction in ED and SUD 
symptoms, indicating that treatment works to reduce problematic personality and behavioural 
tendencies that maintain ED and SUD symptoms. The treatment provided within this study was Int. J. Environ. Res. Public Health 2009, 6          
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lengthy, comprehensive, and intense, and may have served to first reduce PD symptoms, which later 
may have reduced the need to engage in problematic eating and substance use.  
Finally, the reduction in ED, SUD, and PD symptoms might reflect a problem with diagnostic 
assessments. Many symptoms that are characteristic of PDs may be attributable to SUD and ED. For 
example, one of the symptoms of BPD is impulsivity in areas that are self-damaging, such as substance 
use or binge eating, which of course are present in ED and SUD. Other symptoms that are often 
present in ED, SUD, and PD include interpersonal sensitivity, interpersonal distrust, perfectionism, 
fear of criticism, obsessive compulsive behaviours and thinking, and difficulties in identifying and 
describing feelings. It is not clear to which disorder these symptoms should be attributed. Clinicians 
who do assessments might over diagnose or misdiagnose patients with ED and SUD as having PDs in 
this group given the overlap in symptoms between these disorders. Clinicians need to be cognizant that 
in the presence of other co-morbid disorders it can be difficult to accurately diagnose PD, particularly 
when patients have been struggling with concurrent SUD and ED problems for many years. Criteria 
which are used to diagnose PDs may be not applicable to cases with concurrent SUD and ED. It is 
important that clinicians evaluate what is the true source of shared symptoms.  
There are stigmas associated with SUD, ED, and PD. These stigmas are perpetuated by the public, 
patients, and even mental health professionals [53-55]. Of these three disorders, PD may have the 
largest associated stigma. This is partially due to the chronic nature of personality problems, the 
difficulty of maintaining lasting personality change, and the fact that some of the behaviours in which 
these patients engage are perceived as difficult to treat [54-56].  Clinicians and patients can be 
frustrated by these treatment barriers. They can become increasingly negative towards the personality 
dysfunction and the patient’s resistance to change. Clinicians often expect that PD behaviours are 
inflexible, and some are unwilling to work with patients with a PD diagnosis [55,57]. It is important, 
therefore, that clinicians assess patients with ED and SUD carefully, so as not to mislabel symptoms of 
these disorders as personality traits.  
The results of this pilot study and further research in this field could impact the way in which 
clinicians understand PD symptoms in patients with concurrent SUD and ED and could reduce the 
stigma of this population by clinicians who have viewed their patients’ apparent PD symptoms as 
difficult and untreatable. Altering the attitude of patients and clinicians may lead to greater optimism 
about change and therefore better treatment outcomes.  
This study has limitations. The sample is small and involves only outpatients with concurrent SUD, 
ED, and PDs. The results might not be generalizeable and must be interpreted with caution as they 
raise questions that need answering in a larger and more detailed study. Nevertheless, the findings of 
this pilot study are exciting in that they have shown that treatment for ED and SUD may result in the 
remission of PD as well. They offer hope to clinicians and patients who are dealing with such 
concurrent disorders that change is possible, even for what may have been perceived as untreatable. 
They also may serve to remind clinicians to be cautious about diagnosing the existence of PD when 
SUD and ED have co-existed over long periods of time. Furthering this research may help revise 
existing theories of concurrent SUD and ED, and consequently assist clinicians in providing the 
highest level of care possible to patients with these challenging comorbid diagnoses.  
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